跳至主要内容
临床试验/EUCTR2013-001838-17-ES
EUCTR2013-001838-17-ES进行中(未招募)不适用

PROSPECTIVE MULTICENTER CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND, PARALLEL-CONTROLLED VERSUS PLACEBO IN A POLYVALENT SUBLINGUAL BACTERIAL VACCINE (IN ORAL MUCOSA) TO THREE MONTHS AND SIX MONTHS IN WOMEN WITH RECURRENT URINARY TRACT INFECTIONS FOR THE IMMUNOMODULATORY EFFICACY EVALUATION, SAFETY AND CLINICAL IMPACT

Inmunotek, S.L.0 个研究点开始时间: 2015年2月16日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • -Gave written informed consent.
  • -Aged between 18 and 75 years.
  • -They must be able to meet the dosing regimen.
  • -Individuals who have had at least 3 episodes of cystitis in the past 12 months.
  • -Subject that does not have responded to health and hygiene measures and/or suppressive treatments and/or postcoital prophylaxis.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 240
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 240

排除标准

  • -Not have granted the informed written consent.
  • -Not included in the established age range.
  • -Not to offer cooperation I have serious psychiatric disorders.
  • -Present pathological post-voiding residue.
  • -Submit moderada-grave incontinence.
  • -Present genital tumors.
  • -Suffering from urinary tract tumors.
  • -Submit lithiasis.
  • -Present alterations in the immune system.

研究者

发起方
Inmunotek, S.L.

相似试验

Evaluation of the efficacy and safety of MV140 | 临床试验